Table 1.
The basic characteristics of the included studies.
| Study ID | Sex (M/F) | AVG age | N (E/C) | Therapy of experiment | Therapy of control | Course (d) | Outcomes |
|---|---|---|---|---|---|---|---|
| Jiang et al. 2011 [13] | 41/23 | 32–64 | 32/32 | BJOEI 30 ml + XELOX | XELOX | 21 d | ① ② |
| Wang et al. 2013 [14] | 33/29 | 50.2 | 31/31 | BJOEI 30 ml + PTX + ECX | PTX + ECX | 21 d | ① ② |
| Ma et al. 2013 [15] | 38/12 | 60.0 | 25/25 | BJOEI 30 ml + S1 + DDP | S1 + DDP | 14–21 d | ① |
| Wang et al. 2009 [16] | 25/18 | 70–85 | 22/21 | BJOEI 30 ml + UFT + BC | UFT + BC | 30 d | ① ② |
| Liu et al. 2010 [17] | 56/22 | 29–71 | 40/38 | BJOEI 30 ml + DX | DX | 21 d | ① ② |
| Wu et al. 2012 [18] | / | 31–82 | 48/46 | BJOEI 30 ml + FOLFOX4 | FOLFOX4 | 14 d | ① ② |
| Fan et al. 2008 [19] | 27/15 | 70–85 | 24/18 | BJOEI 30 ml + improved FOLFOX4 | Modified FOLFOX4 | 21 d | ①②③ |
| Wang and Yang 2013 [20] | 26/21 | 31–75 | 24/23 | BJOEI 30 ml + FOLFOX4 | FOLFOX4 | 14 d | ① ② ③ |
| Wang and Peng 2012 [21] | 80/50 | 54.7 | 65/65 | BJOEI 20 ml + OXA + CF + Tegafur | OXA + CF + Tegafur | 21 d | ① ② |
| Ma et al. 2014 [22] | 88/20 | 46.8 | 58/50 | BJOEI 20 ml + XELOX | XELOX | 21 d | ① ② ③ |
| Wang 2013 [23] | 40/20 | 52.0 | 31/29 | BJOEI 30 ml + FOLFOX4 | FOLFOX4 | 14–30 d | ① ② ③ |
| Gao 2011 [24] | 29/23 | 32–79 | 26/26 | BJOEI 30 ml + MC/CF | MC/CF | 28 d | ① ② |
| Zhang et al. 2015 [25] | 54/28 | 68.7 | 41/41 | BJOEI 30 ml + XELOX | XELOX | 21 d | ① ② ③ |
Note. M: male; F: female; E: experimental group; C: control group; CF: Leucovorin Calcium; BJOEI: Brucea javanica oil emulsion injection; PTX: Taxol; ECX: capecitabine; DDP: cisplatin; UFT: uracil-FT-207; BC: folic acid; ①: clinical total effective rate; ②: ADRs; ③: performance status.